Recent ANDA Approvals: FDA's Newest Generic Drug Clearances

The timing of generic competition is a foundational input to life-science strategy, shaping loss-of-exclusivity planning, launch sequencing, and pricing decisions across both brand and generic portfolios. Regulatory and clinical teams watch FDA's Office of Generic Drugs closely, because each abbreviated new drug application (ANDA) decision signals where generic entry is arriving next and which reference products are approaching the end of their protected marketing window.

The analysis below reviews FDA's most recent original ANDA actions, covering both full approvals that clear a product for immediate marketing and tentative approvals held back by unexpired patents or exclusivity. It organizes those decisions by active ingredient, dosage form, and first-generic status, with each entry linked back to its FDA source.

Want to ask Rhizome your own regulatory questions? Try it for free.

Recent ANDA approvals: what FDA's newest generics tell you about the 2026 pipeline

Through mid-July 2026, FDA's Office of Generic Drugs acted on 69 original (Orig1) abbreviated new drug applications, spanning full approvals that clear a product for immediate marketing and tentative approvals that are approvable on the merits but held back by unexpired patents or exclusivity on the reference brand 169. Read together, the docket is a useful map of where generic competition is arriving next: it is dominated by oral solid tablets, but it also includes sterile injectables, an intravenous emulsion, ophthalmic drops, an orally disintegrating tablet, and an extended-release oral suspension, and it reaches a series of relatively young brand molecules whose loss-of-exclusivity windows are now opening.

The most recent full approvals

The newest cleared generics are anticoagulant tablets. FDA granted final approval to rivaroxaban tablets from Mankind Pharma (ANDA 220874) on July 1, 2026 and to Micro Labs' rivaroxaban (ANDA 208334) on June 30, 2026 169. Both cover the full 2.5 mg, 10 mg, 15 mg, and 20 mg tablet range and are rated therapeutically equivalent (AB) to Janssen's Xarelto 75. Rivaroxaban is a high-value Factor Xa inhibitor, and two final approvals landing within 48 hours of each other signals active generic competition on the molecule.

Other recent full approvals include:

  • Baloxavir marboxil tablets, 40 mg and 80 mg, from Norwich (ANDA 217449), approved June 17, 2026, AB-rated to Genentech's Xofluza 31139. Xofluza was a 2021 brand approval, so this is an early generic entry for the single-dose influenza antiviral 139.
  • Solriamfetol hydrochloride tablets from Alkem (ANDA 218722), June 17, 2026, referencing Sunosi (brand approved 2019) for excessive daytime sleepiness 25201.
  • Macitentan 10 mg tablets from Amneal (ANDA 211000), June 8, 2026, AB-rated to the pulmonary arterial hypertension brand Opsumit 59156.
  • Tofacitinib citrate tablets from MSN (ANDA 217298) and Aurobindo (ANDA 215356), both June 3, 2026, referencing the JAK inhibitor Xeljanz 3237131.
  • Cephalexin from Aurobindo (ANDA 213568), June 9, 2026 44; cangrelor from MSN (ANDA 213703), June 4, 2026 43; linagliptin 5 mg tablets from Teva (ANDA 208433), May 27, 2026, referencing Tradjenta 68101; and a sodium sulfate / magnesium sulfate / potassium chloride bowel-prep from Lupin (ANDA 216095), May 28, 2026 35.
  • Clonazepam orally disintegrating tablets from Rubicon Research (ANDA 216988), May 21, 2026, across the full 0.125 mg to 2 mg ODT range, AB-rated to Klonopin 33137.

First-generic milestones and newly opened brand molecules

Several 2026 approvals are the arrival of generic competition for brands that are still comparatively young, which is where the commercial significance concentrates.

Dapagliflozin (Farxiga) was the marquee event. On a single day, April 6, 2026, FDA granted final approval to a cluster of dapagliflozin products: standalone dapagliflozin tablets (5 mg and 10 mg) from Alembic, Ajanta, Biocon, Micro Labs, Sandoz, Inventia and others 515455565758; the dapagliflozin/metformin extended-release combination from Teva and Alkem 4950; and the dapagliflozin/saxagliptin combination from MSN 53. All reference AstraZeneca's SGLT2-inhibitor franchise, Farxiga and the fixed-dose combinations Xigduo XR and Qternmet XR 190193195. A same-day wave of approvals across a dozen sponsors is the classic footprint of a first-generic launch keyed to a patent-and-exclusivity cliff.

Canagliflozin (Invokana) followed a similar path: Apotex received final approval for canagliflozin 100 mg and 300 mg tablets on April 14, 2026, AB-rated to Janssen's Invokana 6579. Together with the dapagliflozin cluster, this marks broad generic entry into the SGLT2-inhibitor class within a two-week window.

Other notable first-wave generics of recent brands:

  • Enzalutamide tablets, 40 mg and 80 mg, from Sandoz (ANDA 216068), April 20, 2026, AB-rated to Astellas' prostate-cancer brand Xtandi (2020 brand approval) 36199.
  • Nintedanib esylate capsules, 100 mg and 150 mg base, from Apotex (ANDA 219227) and Cipla (ANDA 212609), April 2, 2026, referencing Boehringer Ingelheim's Ofev 2047127.
  • Idelalisib tablets from Natco (ANDA 216921), February 17, 2026, referencing Gilead's Zydelig 34106.
  • Ferric citrate tablets from Teva (ANDA 212563), March 11, 2026, referencing Auryxia 48159.
  • Ticagrelor tablets, 60 mg and 90 mg, from Mankind (ANDA 217679), February 6, 2026, AB-rated to Brilinta 30147.
  • Brivaracetam from MSN (ANDA 214924), February 23, 2026, referencing UCB's antiepileptic Briviact 39206.

A caution for readers tracking "first generic" status precisely: FDA maintains a formal first-generic designation list, and the agency's competitive-generic-therapy determinations are not captured in the approval letters or Orange Book records reviewed here. The approvals above are best characterized as early or first-wave generic entrants for their reference brands based on the approval record and reference-brand approval dates; confirming a formal first-generic designation for any individual product would require checking FDA's first-generics publication directly.

Dosage-form and complexity signals

While oral tablets dominate, the 2026 docket includes several harder-to-copy presentations that matter for generic-development strategy:

  • Sterile injectables: bortezomib for injection (1 mg and 2.5 mg per vial) from Gland (ANDA 219167), January 6, 2026, rated AP and referencing Velcade 21149; and Apotex's multi-ingredient adult and pediatric multiple vitamins for injection (ANDAs 210672, 210671, 210456, 210273), approved April 2026 62636466.
  • Intravenous emulsion: aprepitant IV emulsion (32 mg/4.4 mL) from Mylan (ANDA 218851), March 5, 2026, in the Cinvanti/Aponvie space (the product is now shown as discontinued in Drugs@FDA) 23187189.
  • Extended-release oral suspension: mirabegron for extended-release suspension (8 mg/mL) from Alkem (ANDA 219323), January 20, 2026, referencing Myrbetriq Granules 18212.
  • Orally disintegrating tablet: clonazepam ODT from Rubicon 33.
  • Ophthalmic: olopatadine hydrochloride 0.7% ophthalmic solution from Gland (ANDA 213514), an over-the-counter switch product 45.
  • Inhalation and nasal: albuterol sulfate from Cipla (ANDA 219409) 17, ipratropium bromide from Armstrong (ANDA 217953) 29, and fluticasone propionate from Glenmark (ANDA 219602) 15, all approved in early 2026.

These complex-generic approvals, particularly the injectables, IV emulsion, ER suspension and inhalation products, reflect where generic manufacturers are investing to differentiate beyond commodity oral solids.

Tentative approvals: approvable but blocked

A substantial share of the 2026 docket is tentative approvals, where FDA has found the ANDA scientifically and administratively approvable but marketing is barred by unexpired patents or exclusivity on the brand. These are leading indicators of generic competition that is queued but not yet live:

  • Vericiguat, referencing Merck's heart-failure brand Verquvo (2021), tentatively approved for Changzhou Pharmaceutical Factory and Torrent 78204.
  • Erdafitinib, referencing Janssen's Balversa (2019), tentative approval for Natco 26205.
  • Cenobamate, referencing SK Life Science's antiepileptic Xcopri (2020), tentative approval for Aurobindo 16198.
  • Pitolisant, referencing Harmony Biosciences' narcolepsy brand Wakix (2019), tentative approval for Novitium 28107.
  • Afatinib, referencing Boehringer Ingelheim's Gilotrif, tentative approval for MSN 61128.
  • Sitagliptin phosphate, referencing Merck's Januvia, tentative approval for Alkem 38118.
  • Gabapentin enacarbil (Annora) 3, viloxazine hydrochloride (Appco) 4, amphetamine (Granules) 6, rifaximin (Mylan) 14, and the four-drug HIV combination elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Apotex) 27 round out the tentative-approval group.

For pipeline planning, the tentative-approval list is where to watch: once the blocking patent or exclusivity on Verquvo, Balversa, Xcopri, Wakix or Januvia lapses, these approvals can convert to final approval and reach the market quickly, often as the first generics of those molecules.

What to take from the docket

The recency of the reference brands is the throughline. FDA is now clearing generics of molecules first approved between 2019 and 2021 (baloxavir, solriamfetol, vericiguat, cenobamate, pitolisant, erdafitinib), alongside broad first-wave entry into the SGLT2-inhibitor class (dapagliflozin, canagliflozin) and continued competition on established anticoagulants and antiplatelets (rivaroxaban, ticagrelor). The mix of final versus tentative approvals also cleanly separates molecules where competition is live from those where it is patent-gated and pending. For a deeper look at any single molecule, the exclusivity and patent picture behind the tentative approvals, the therapeutic-equivalence codes and strengths of a specific product, or the reference-brand IP that is gating a launch, those Orange Book details can be pulled product by product.